Sutro Biopharma, Inc. · 15 hours ago
Sr. Accounts Payable Specialist (Contract)
Sutro Biopharma, Inc. is seeking a Senior Accounts Payable Specialist (Contract) to join our team and play a critical role in managing our accounts payable processes. In this position, you will ensure the timely and accurate processing of vendor invoices and payments while maintaining strong relationships with our vendors and contributing to the overall efficiency of the finance department.
BiotechnologyInformation TechnologyMedical
Responsibilities
Invoice Processing: Review, verify, and process a high volume of invoices in accordance with company policies and procedures
Vendor Management: Build and maintain positive relationships with vendors, addressing discrepancies and inquiries regarding invoices and payments
Payment Processing: Prepare and execute payment runs, including checks and electronic transfers, ensuring timely and accurate disbursements
Reconciliations: Conduct regular account reconciliations, resolve discrepancies, and assist with month-end closing activities
Process Improvement: Identify and implement enhancements to streamline the accounts payable workflow and improve overall efficiency
Compliance: Ensure compliance with internal controls and regulatory requirements related to accounts payable
Qualification
Required
Bachelor's degree in accounting, Finance, or a related field preferred
5+ years of accounts payable experience, with a strong understanding of AP processes
Proficiency in accounting software and ERP systems (e.g., D365, Oracle, QuickBooks)
Proven to review, verify, and process a high volume of invoices
High attention to detail and accuracy
Strong analytical and problem-solving skills
Excellent communication and interpersonal skills
Ability to work independently and collaboratively in a fast-paced environment
Preferred
Knowledge of D365 Finance and Operations or similar ERP system is a plus
Company
Sutro Biopharma, Inc.
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients.
Funding
Current Stage
Public CompanyTotal Funding
$636.61MKey Investors
Blackstone Life SciencesSkyline VenturesSV Health Investors
2024-04-02Post Ipo Equity· $75M
2023-06-26Post Ipo Debt· $140M
2020-12-14Post Ipo Equity· $144.9M
Recent News
2026-01-07
Canada NewsWire
2025-12-19
2025-12-17
Company data provided by crunchbase